✦ LIBER ✦

Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia

✍ Scribed by M. Samir Arnaout; Fouad P. Antun; Khalil Ashkar

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 39 KB
Volume: 16
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.250

No coin nor oath required. For personal study only.

✦ Synopsis

A 30-year-old white man with schizophrenia developed anorexia and nausea, and was admitted to hospital for confusion and delirium. He was on olanzapine, 10 days prior to admission. On admission, typical neuroleptic malignant syndrome (NMS) developed with elevated body temperature (39.7 degrees C), obtundation, tremor, rigidity, diaphoresis, fluctuating pupillary diameter, tachycardia, labile hypertension, elevated serum creatine kinase and severe hypernatremia (190 meq/l). Olanzepine was stopped few days after admission to the hospital and the NMS manifestations resolved by hospital day 12. The patient had all of the major manifestations of NMS. There was no other likely explanation for his illness. This is the first case reported in which NMS was associated with olanzapine and extremely elevated levels of serum sodium. Copyright 2001 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Olanzapine associated weight gain, Hyper

Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report

✍ Rhonda Malyuk; Bruce Gibson; Ric M. Procyshyn; Nirmal Kang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

## Abstract We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year‐old woman with a significant medical history. Eighteen weeks after initiating olanzapine, Mrs X lost glycemic control, exhibited signs and symptoms consistent with

Neuroleptic malignant-like syndrome asso

Neuroleptic malignant-like syndrome associated with acute hydrocephalus

✍ Chin-Song Lu; Shan-Jin Ryu 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB

Treatment of neuroleptic malignant syndr

Treatment of neuroleptic malignant syndrome with levodopa

✍ K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic

Clozapine-induced neuroleptic malignant

Clozapine-induced neuroleptic malignant syndrome not recurring with olanzapine, a structurally and pharmacologically similar antipsychotic

✍ Franco Benazzi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Clozapine-induced neuroleptic malignant syndrome not recurring with olanzapine, a structurally and pharmacologically similar antipsychotic

Neuroleptic malignant syndrome treated w

Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion

✍ M. E. Rodriguez; M. R. Luquin; G. Lera; G. Delgado; J. M. Salazar; Dr. José A. O 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

## Abstract A schizophrenic patient developed a characteristic clinical picture of neuroleptic malignant syndrome (NMS) while admitted to the hospital during an exacerbation of his psychiatric symptoms. Oral treatment of the NMS with bromocriptine (7.5 mg/day) or levodopa/carbidopa (125/12.5 mg) pr

Neuroleptic malignant syndrome associate

Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent

✍ Heidi Lee; James Ryan; George Mullett; Brian A. Lawlor 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Neuroleptic malignant syndrome (NMS) is a rare and sometimes fatal adverse reaction to neuroleptic drugs. Atypical antipsychotic agents, such as risperidone, are thought to be less likely to cause N M S because of their phamacologiical profile. This is a case report of NMS associated with risperidon